<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="823">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390464</url>
  </required_header>
  <id_info>
    <org_study_id>TACTIC-R</org_study_id>
    <nct_id>NCT04390464</nct_id>
  </id_info>
  <brief_title>mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)</brief_title>
  <acronym>TACTIC-R</acronym>
  <official_title>mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TACTIC-R is a randomised, parallel arm, open-label platform trial for investigating potential
      treatment for COVID-19 disease. While SARS-CoV infection evades detection by the immune
      system in the first 24 hours of infection, it ultimately produces a massive immune system
      response in the subgroup of people who develop severe complications. Most tissue damage
      following infection with COVID19 appears to be due to a later, exaggerated, host immune
      response. This leads to lung and sometimes multi-organ damage.

      Most people who develop these severe complications still have virus present in their
      respiratory tract at the time-point when the disease starts to evolve. Immune modulation in
      the presence of active infection has potential to cause more harm than benefit. Safety
      considerations when studying immune modulation strategies are paramount. Therefore, this
      study proposes to assess the efficacy of immunomodulatory agents that target dysregulated
      immune response that drive the severe lung, and other organ, damage. The medications
      investigated for efficacy in this trial are Baricitinib and Ravulizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TACTIC-R will assess the efficacy of the immunomodulatory agents Baricitinib and Ravulizumab
      as potential treatments for COVID-19 disease against Standard of Care alone. These agents
      target the dysregulated immune response that drives the severe lung, and other organ, damage
      frequently seen during COVID-19 infection. This trial will compare these immunomodulatory
      agents to Standard of Care over a 14-day treatment period, with follow-up at 28 and 90 days.
      Patients will be randomised in a 1:1:1 ratio across treatments.

      TACTIC-R will use a platform design with interim analysis to make efficient decisions about
      efficacy and futility (e.g. lack of efficacy and risk of harm) of the trial treatments. This
      enables the trial to stop recruiting to arms early where a clear efficacy decision can be
      made. It also allows for the addition of further arms.

      TACTIC-R will also iterate an algorithm for use of clinical and biochemical phenotyping to:

        1. Stratify patients to therapeutic arms according to probability of efficacy

        2. Identify early indicators of failure of therapeutic strategy.

      By collecting samples for genomics, transcriptomics, proteomics and immunological
      phenotyping, parallel studies associated with TACTIC-R will investigate host susceptibility
      factors for development of severe COVID-19-related disease and predictive biomarkers of
      response to therapeutic strategy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>TACTIC-R is a randomised, parallel arm, open-label platform trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure</measure>
    <time_frame>up to Day 14</time_frame>
    <description>Number of days taken for occurrence of one of the following events: 1. Death 2. Mechanical ventilation 3. Extracorporeal membrane oxygenation (ECMO) 4. Cardiovascular organ support (balloon pump or inotropes) 5. Renal failure (estimated creatinine clearance (by Cockcroft-Gault formula) &lt;15 ml /min/1.73m^2), haemofiltration or dialysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status as assessed on 7-point ordinal scale compared to baseline</measure>
    <time_frame>14 days</time_frame>
    <description>The clinical status of the patients is assessed using 7-point ordinal scale as follows: 1 = Death, 2 = Mechanical ventilation, 3 = Non-invasive or high flow oxygen, 4 = Low flow oxygen, 5 = Hospitalised - no oxygen, 6 = Discharged - normal activities not resumed, 7 = Discharged - normal activities resumed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse events of special interest in each treatment arm</measure>
    <time_frame>14 days</time_frame>
    <description>The proportion of patients in each treatment arm that experience adverse events of special interest, defined as: venous thromboembolism, new infections requiring antimicrobials</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sp02 &gt;94% on room air</measure>
    <time_frame>14 days</time_frame>
    <description>The time taken to achieve blood oxygen saturation levels above 94% in patients on room air, measured in hours/days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first negative SARS-CoV2 PCR</measure>
    <time_frame>14 days</time_frame>
    <description>The amount of time between a patient's first positive SARS-CoV2 PCR test and a patient's first negative SARS-CoV2 PCR test, measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygen therapy</measure>
    <time_frame>14 days</time_frame>
    <description>The duration of oxygen therapy given to a patient, measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation</measure>
    <time_frame>14 days</time_frame>
    <description>The duration of hospitalisation of a patient, measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality at day 28</measure>
    <time_frame>28 Days</time_frame>
    <description>The number of deaths recorded at 28 days irrespective of the cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>14 days</time_frame>
    <description>The time to clinical improvement for a patient, defined as: &gt;2 point improvement from Day 1 on the 7-point ordinal scale, measured in days</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1167</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ravulizumab + Standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ravulizumab IV (adjusted to weight, Day 1 only)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib + Standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib PO OD (4mg, Days 1-14)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravulizumab</intervention_name>
    <description>Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.</description>
    <arm_group_label>Ravulizumab + Standard of care</arm_group_label>
    <other_name>Ultomiris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Baricitinib is administered orally once daily. It is licensed for treatment of rheumatoid arthritis, it is a relatively fast acting disease modifying anti-rheumatic drug and has the potential to be scaled up for use for a pandemic.</description>
    <arm_group_label>Baricitinib + Standard of care</arm_group_label>
    <other_name>Olumiant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Regular standard of care for COVID-19 patients</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        To be included in the trial the participant must:

          1. Be aged 18 and over

          2. Have clinical picture strongly suggestive of COVID-19-related (with/without positive
             COVID-19 test) AND

               -  Risk count (as defined below) &gt;3 OR

               -  â‰¥ 3 if risk count includes &quot;Radiographic severity score &gt;3&quot;

          3. Be considered an appropriate subject for intervention with immunomodulatory in the
             opinion of the supervising clinician

          4. Be able to be maintained on venous thromboembolism prophylaxis or current maintenance
             therapy during inpatient dosing period, according to local guidelines

        Exclusion Criteria

        The presence of any of the following will preclude participant inclusion:

          1. Inability to supply direct informed consent or assent from Next of Kin or Independent
             Healthcare Provider on behalf of patient

          2. Mechanical ventilation at time of prior to dosing

          3. Contraindications to study drugs, including hypersensitivity to the active substances
             or any of the excipients

          4. Currently on any of the study investigational medicinal products

          5. Known unresolved Neisseria meningitidis infection

          6. Unwilling to be vaccinated against Neisseria meningitidis or receive prophylactic
             antibiotic cover until 2 weeks after vaccination

          7. Known active tuberculosis (no blood screening required)

          8. Known active Hepatitis B or C (no blood screening required); active varicella zoster

          9. Concurrent participation in any interventional clinical trial including
             COVID-19-related disease trials (observational studies allowed)

         10. Patient moribund at presentation or screening

         11. Pregnancy at screening (or unwillingness to adhere to pregnancy advice in protocol)

         12. Unwillingness to adhere to breastfeeding advice in protocol

         13. Either alanine transaminase or aspartate transaminase (ALT or AST) &gt; 5 times the upper
             limit of normal

         14. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. Cockcroft Gault
             estimated creatinine clearance &lt; 30 ml /min/1.73 m^2)

         15. Currently receiving probenecid or chronic IVIG treatment

         16. Any medical history or clinically relevant abnormality that is deemed by the principal
             investigator and/or medical monitor to make the patient ineligible for inclusion
             because of a safety concern.

        Risk Count

        Patients will be given a Risk Count equal to the cumulative points received for the
        following criteria (no = 0 points, yes = 1 point):

        Male gender, Age &gt; 40 years, Non-white ethnicity, Diabetes, Hypertension, Neutrophils &gt;
        8.0x10^9/L, CRP &gt; 40mg/L, Radiographic severity score &gt;3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances Hall Hall, FRCP (UK), D.Phil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Hernan-Sancho</last_name>
    <phone>01223 349132</phone>
    <phone_ext>349132</phone_ext>
    <email>elena.hernansancho@addenbrookes.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Hernan Sanch0</last_name>
      <phone>01223369824</phone>
      <email>elena.hernansancho@addenbrookes.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Maria King</last_name>
      <phone>07792173955</phone>
      <email>maria.king@addenbrookes.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Frances Hall</investigator_full_name>
    <investigator_title>Consultant Rheumatologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ravulizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

